788 Improved immunologic and therapeutic activity of anchored interleukin (IL-12) immunotherapy in combination with cytotoxic chemotherapy and immune checkpoint inhibitor in a head and neck cancer model

• Jeffrey Schlom,
• Leisha A Emens,
• Howard Kaufman,
• James Hodge,
• Sailaja Battula,
• Kellsye Fabian,
• Ginette Santiago-Sanchez

Affiliations

Jeffrey Schlom

1National Cancer Institute, National Institutes of Health, Bethesda

Leisha A Emens

3Ankyra Therapeutics, Pittsburgh, PA, USA

Howard Kaufman

4Ankyra Therapeutics/Massachusetts General Hospital, Boston, MA, USA

James Hodge

1National Cancer Institute, National Institutes of Health, Bethesda

Sailaja Battula

2Ankyra Therapeutics, Boston, MA, USA

Kellsye Fabian

1National Cancer Institute, National Institutes of Health, Bethesda

Ginette Santiago-Sanchez

1National Cancer Institute, National Institutes of Health, Bethesda